Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients

Fig. 2

Kaplan-Meier analysis of overall survival in ipilimumab treated melanoma patients. Overall survival for patients with biomarker levels in the upper quartile (Q4) vs the lower quartiles (Q1 + Q2 + Q3) for PRO-C3, C1M, C3M and C4M, while for VICM it is the upper quartiles (Q3 + Q4) vs the lower quartiles (Q1 + Q2). A log-rank test was used to determine differences between the survival curves where a p-value of p < 0.05 was considered statistically significant

Back to article page